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Introduction
Macrophage activation syndrome is a term used to iden-
tify hemophagocytic lymphohistiocytosis secondary to
rheumatic diseases (rheuHLH). It is a severe, potentially
fatal condition that occurs in the context of rheumatic
diseases, particularly systemic juvenile idiopathic arthri-
tis. It is part of secondary HLH forms, that are clinically
and biochemically similar to primary HLH (pHLH), with
generalized hypercytokinemia as a major feature. While
the triggering mechanism behind pHLH is the defect in
cytotoxicity, caused by mutations in genes encoding
proteins required for lymphocyte and natural killer cell
activity, the rheuHLH pathogenesis is not clearly
understood.
Objectives
Based on data obtained in animal models of pHLH,
showing that interferon-gamma (IFN-g) neutralization
reverts the disease, we aim to demonstrate, in a murine
model of rheuHLH, the role of IFN-g and the efficacy of
an anti-IFN-g antibody.
Materials and methods
A mouse model of rheuHLH (Strippoli R, Arthritis
Rheum 2012), recently developed in our laboratory,
relying on an exaggerated response to toll-like receptor
ligands in mice transgenic for the pro-inflammatory
cytokine interleukin-6 (IL6TG), has been used to eval-
uate levels of IFN-g and the therapeutic potential of a
rat neutralizing IFN-g antibody (XMG1.2, BioXcell,
USA).
Results
LPS-treated IL-6TG mice showed an exaggerated
inflammatory response, with significantly higher IFN-g
mRNA expression levels in liver and spleen, compared
to LPS-treated WT mice. Moreover, we observed a sig-
nificant increase in the expression of genes known to be
induced by IFN-g, such as CXCL9, CXCL10 and H2-Aa
(class II antigen A, alpha), in the spleen and in the liver
from LPS-treated IL-6TG mice compared to WT mice.
IFN-g neutralization studies have revealed that, in LPS-
injected IL-6TG mice, anti-IFN-g treatment significantly
improves survival and body weight recovery, compared
to control antibody-treated animals. Furthermore, a sig-
nificant reduction in ferritin levels was observed in mice
treated with anti-IFN-g Ab, compared to control anti-
body-treated animals. Finally, a significant reduction in
the mRNA expression of IFN-g-induced genes was
observed in spleen and liver from mice treated with
anti-IFN-g Ab.
Conclusion
These data demonstrate that the IFN-g pathway is up-
regulated in LPS-treated IL-6TG mice, compared to the
wild type mice. Neutralization of IFN-g significantly
improves survival and clinical hematological parameters.
These results provide insights into the pathophysiology
of rheu-HLH, further support the hypothesis that IFN-g
is the common mediator of all HLH forms and provide
the rational for the therapeutic use of a monoclonal
anti- IFN-g antibody in this fatal disorder.
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